Düsseldorf, Germany – Sept. 11, 2009 – Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI® (natalizumab) experienced an improvement in both their physical function and psychological well-being. Findings from the study, which was performed in conjunction with HealthCore Inc., a health-outcomes research company, are the first attempt to assess patient experiences with TYSABRI in usual-care settings. The data, presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), shows patients report TYSABRI has an impact in improving their overall quality of life.
"The symptoms that an MS patient deals with on a daily basis result in significant psychological and physical effects that can adversely impact their quality of life," said William Stuart, M.D., medical director of the Multiple Sclerosis Center of Atlanta. "In a previous pivotal trial, TYSABRI not only showed a reduction in relapse rates and disability progression, but also improved quality of life. Results from this observational study further demonstrate the impact of TYSABRI on improving MS patients' well-being as reported by patients who live with this disease every day."
About the study
The study is assessing health outcomes from patients' perspectives before starting TYSABRI and after the third, sixth and 12th infusions of TYSABRI. A majority of the patients in the study are female (76.3%) with mean age of 46.6 years and mean disease duration of 10 years.
After six TYSABRI infusions, patients reported statistically significant improvement in:
Both scales assess patient experience of the physical and psychological aspects of QoL. For the MSIS-29 subscales, there were statistically significant improvements over time for both the physical (baseline 46.87; third infusion 39.60; sixth infusion 39.27 (p< 0.001)) and psychological (baseline 41.56; third infusion 33.77; sixth infusion 33.20 (p< 0.001)) impact scores.
SF-12 physical component summary (baseline 34.20; third infusion 36.05; sixth infusion 36.34 (p< 0.001)) and the SF-12 mental component summary score (baseline 43.25, third infusion 47.35, sixth infusion 47.92 (p< 0.001)) showed statistically significant improvements over time.
What do multiple sclerosis patients experience? Effect of natalizumab on disease-specific quality of life over time (poster P872).